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Abstract: A 13-year-old castrated male Shih Tzu was presented with recurrent otitis externa and ulcerative dermatitis. Previous
investigations had failed to identify the cause, and the lesion was resistant to treatment. According to the histopathological examination,
a tentative diagnosis of chronic ulcerative dermatitis with bacterial infection was made. To treat the patient, immune cell therapy
with antibiotics was conducted every 2 weeks, for a total of six sessions. After treatment, the skin lesion resolved. No side effects were
observed during therapy. To the best of our knowledge, this is the first case report of the use of immune cell therapy for canine ulcerative
dermatitis.
Key words: Activated lymphocytes, dog, ex vivo boosted immune cells, ulcerative dermatitis

1. Introduction
Canine ulcerative dermatitis is induced by several causes.
The main causes of this skin condition are infections
including fungi, bacteria, and ectoparasites, along
with autoimmune skin diseases such as pemphigoid
and systemic lupus erythematosus (1–4). Differential
diagnoses include neoplasia, thermal or chemical burns,
and reactions to injections (5). Definitive diagnosis
depends on excluding the differential diagnoses via history
taking, dermatological examination, and characteristic
histopathology of the skin samples (4).
Ex vivo boosted immune cell (EBIC) therapy is
referred to as transfusion therapy with lymphokineactivated T killer cells (T-LAK) in human medicine (6). In
EBIC therapy, the patient receives a number of activated
immune cells isolated from the patient’s peripheral blood
mononuclear cells (PBMCs), which have been expanded ex
vivo. In humans, this immunotherapy is commonly used to
treat cancer patients (6). In dogs, several studies on T-LAK
have been conducted and demonstrated reinforcement of
the recipient’s immunity with this therapy (7,8).
This case report describes canine chronic ulcerative
dermatitis with resistance to several therapeutic agents
that was finally controlled with immune cell therapy and
antibiotics.
2. Case history
A 13-year-old castrated male Shih Tzu presenting with
recurrent otitis externa and dermatitis was referred to our

clinic. He was treated with topical and systemic antibiotics
and prednisolone for 9 weeks at a local hospital, but the
treatments were ineffective.
Physical examination revealed bilateral skin lesions on
the periocular, ear, axillary, groin, hind leg, and perianal
regions. The skin lesions were severely erythematic and
ulcerative with exudate and superficial crust (Figure 1).
Cytology revealed severe cocci infection with massive
neutrophils. The wood ramp test was negative. The
complete blood count and serum biochemistry profile
revealed low white blood cell count (3.13 U/L, reference
interval [RI] = 6.70–18.3 U/L), high alkaline phosphatase
(>3500 U/L, RI = 14–224 U/L), high gamma-glutamyl
transferase (74 U/L, RI = 1–14 U/L), and high alanine
aminotransferase (578 U/L, RI = 4–125 U/L). Antibiotic
susceptibility results indicated that chloramphenicol and
amoxicillin/clavulanic acid were suitable. Skin biopsy
specimens were obtained from the right flank cutaneous
lesions. Upon histopathological examination of the skin
sample, the patient was diagnosed with chronic ulcerative
dermatitis. Severe vesicular crust was observed in the
upper area of the ulcer. Superficial crusting was evident at
the surface and comprised neutrophils, keratin debris, and
fibrin. Degenerated neutrophils infiltrated the superficial
dermis, and lymphocytes and macrophages infiltrated the
dermis and subcutis. Moth-eaten appearance was noted at
the derma-epidermal junction. No acantholytic cells were
observed. There was no evidence of neoplastic changes or
autoimmune processes. Fungal stains were applied to the
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Figure 1. The ulcerative skin lesions before EBICs therapy: a) right ear, b) axillary region, c) perianal region, d) hind legs.

tissue, but no organisms were present. According to the
antibiotic susceptibility results, the patient was treated with
chloramphenicol (40 mg/kg; Helocetin; Chongkundang,
Seoul, South Korea) and amoxicillin/clavulanic acid (20
mg/kg; Amocla; Kuhail, Chunan, South Korea) twice per
day orally for 2 weeks. However, there was no response to
antibiotics and no regression of skin lesions. The pruritus
and exudate worsened. Following consultation with the
patient’s owner, the decision was made to conduct EBIC
therapy with antibiotics. For autologous lymphocyte
culture and expansion, a 10-mL blood sample was
obtained from the patient’s jugular vein every 2 weeks.
The PBMCs were isolated from blood samples and were
cultured and expanded ex vivo for 13 days. Interleukin-2
(IL-2) was used as a mitogen for lymphocyte activation.
The isolation, culture, and expansion procedures for
immune cells were obtained and modified from previous
studies (7,8). The phenotypes of cells before and after
processing were analyzed by flow cytometry, and the
outcomes are presented in Figure 2. After expansion, the
EBICs were suspended in 20 mL of standard saline and
injected intravenously into the patient. The number of
injected EBICs at each treatment session is provided in
the Table. EBIC therapy was conducted every 2 weeks
for a total of 6 sessions, and all skin lesions were resolved
following treatment (Figure 3). During the therapy, no side
effects were observed and blood examination revealed no
abnormalities.
3. Results and discussion
Many skin diseases induce erosion and crusting
secondary to intense inflammation and through selftrauma from pruritus (4). In recurrent or chronic
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Figure 2. Phenotypes of immune cells before and after ex vivo
culture. To clarify the cellular phenotype of PBMCs and EBICs,
flow cytometric analysis was performed. The results are presented
as mean ± standard deviation. A comparison between PBMCs
and EBICs was performed with the paired t-test. a) Phenotypes
of PBMCs, b) phenotypes of EBICs. *P < 0.05.
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Table. The characteristics of injected EBICs.

Expansion (fold)
Number of injected EBICs (×10 cells)
8

1st

2nd

3rd

4th

5th

6th

Average

18.4

8.8

143.3

335

240.4

390.9

240

1.7

0.9

5.0

5.0

5.0

5.0

3.77

Figure 3. The skin after 6 sessions of EBICs therapy. All skin lesions resolved clearly. a) Right ear, b) axillary region, c) perianal region,
d) hind legs.

ulcerative dermatitis, history taking, cytology, and skin
biopsy should be performed to identify the causative
factor (4). In this case, the patient had suffered recurrent
external otitis and chronic ulcerative dermatitis. He
had been previously treated with several systemic and
topical antibiotics and antiinflammatory drugs with no
response. Via careful examination, adverse cutaneous
drug reaction, autoimmune skin disease, fungal infection,
and neoplasia were eliminated as causative factors. Only
severe cocci infection remained. Few studies have reported
mucocutaneous pyoderma (MCP) in dogs (2,4). MCP is
an ulcerative dermatosis of unknown etiology. Dogs with
MCP present bilaterally symmetrical skin lesions with
mild to moderately pruritic erythema and crusting. The
locations of skin lesions include the anus, nares, periocular,
or vulva/prepuce. Generally, MCP may respond well
to antimicrobial therapy. However, in the present case,
antimicrobial therapy was not effective, with the exception
of the choice of drug based on cytology and antibiotic
susceptibility test. Thus, EBIC therapy with antibiotic
therapy was conducted.
In previous studies, administration of ex vivo
activated lymphocytes in dogs could lead to resolution
of inflammation and reinforce the recipient’s immunity
(7,8). In the present case, the number of cells increased
by an average of 240-fold after culture and an average
of 3.77 × 108 cells/session were injected into the patient.
Flow cytometric analysis was performed to clarify the
cellular phenotype of PBMCs and EBICs. The cells

comprised T lymphocytes (CD3+CD21+), B lymphocytes
(CD21+), helper T cells (CD3+CD4+CD8-), and cytotoxic
T cells (CD3+CD4-CD8+). A comparison between PBMCs
and EBICs was performed with the paired t-test. The
proportion of T lymphocytes was predominant in both
PBMCs (mean: 89.10%) and EBICs (mean: 99.04%).
Following ex vivo expansion, the proportion of cytotoxic T
cells increased significantly from 39.69% to 63.79%. These
results were similar to those of previous studies (7,8). For
a long time, cytotoxic T cells were considered to have the
ability to kill tumor, allogenic, and virus-infected cells (9–
11). In addition, several recent reports have demonstrated
that cytotoxic T cells also have the ability to directly
recognize and kill bacteria, parasites, and fungi (12). There
were no studies regarding the correlation between T-cell
therapy and infection in veterinary clinics. However,
human PBMCs stimulated by IL-2 were found to inhibit
the growth of microorganisms and T-cell therapy was
considered a novel treatment for infectious disease (12).
In this case, during EBIC therapy, there was no change
in patient activity or appetite and no adverse effects
were observed. After 6 EBIC therapy sessions, all skin
lesions had clearly resolved and there was no recurrence
for 2 years. To the best of our knowledge, this is the first
case report of the use of immune cell therapy for canine
ulcerative dermatitis with bacterial infection. We could not
explain the specific mechanism of action of EBIC therapy.
However, we expect that this therapy could be used to treat
refractory, antibiotic-resistant dermatitis.
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